New hope for CLL patients with stubborn cancer cells
NCT ID NCT04501939
Summary
This study is testing whether adding a new drug called cirmtuzumab to existing venetoclax treatment can help eliminate remaining cancer cells in people with chronic lymphocytic leukemia. The trial involves patients who have been on venetoclax for at least a year but still show detectable cancer. Researchers want to see if this combination can achieve undetectable disease levels and delay the need for further treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSD Koman Family Outpatient Pavilion
San Diego, California, 92037, United States
Conditions
Explore the condition pages connected to this study.